Sépult, Christelle
Bellefroid, Marine
Rocks, Natacha
Donati, Kim
Gérard, Catherine
Gilles, Christine
Ludwig, Andreas
Duysinx, Bernard
Noël, Agnès
Cataldo, Didier http://orcid.org/0000-0002-3079-7941
Funding for this research was provided by:
Fonds De La Recherche Scientifique - FNRS (7463213F, 7457116F, 7653418F, 7463012F)
Stichting Tegen Kanker (FA/2014/314)
Interuniversity Attraction Poles Belgian Federal gouvernment P7/30
Article History
Received: 12 July 2018
Revised: 28 November 2018
Accepted: 14 December 2018
First Online: 16 January 2019
Compliance with ethical standards
:
: DC is the founder of Aquilon Pharmaceuticals, received speaker fees from AstraZeneca, Boehringer Ingelheim, Novartis, Mundipharma, Chiesi and GSK and received consultancy fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK and Novartis for the participation to advisory boards. None of these activities are related to the therapy of cancer or mesothelioma.
: The experimental protocols for animal studies were examined and approved on 6 May 2011 and 26 May 2016 by Ethical Committee (University of Liege) and accepted under the reference numbers #1201 and #1757. The study protocol for human samples was approved by the Ethical Committee of University hospital of Liège (CHU) on 9 October 2012 and accepted under the reference number #B707201215113.